‘Uber for Getting Off Antidepressants’ Launches in the US
Outro, which is now available in seven states, wants to help people taper off antidepressants without experiencing debilitating side effects.
Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 medication injected daily instead of weekly.
DOGE’s Cuts at the USDA Could Cause US Grocery Prices to Rise and Invasive Species to Spread
Thousands of US Department of Agriculture employees, including food inspectors and disease-sniffing dog trainers, remain out of work, leaving food to rot in ports and pests to proliferate.
A Lethal Mystery Illness Is Spreading in Congo. USAID Cuts Have Slowed the Response
Gutting USAID is already having a devastating impact around the world. In the Democratic Republic of Congo, teams that would normally be racing to identify a fatal sickness are gone.
USAID Was Promised Emergency Waivers for Ebola and AIDS. They’re Not Working
Elon Musk claims he mistakenly fired Ebola prevention workers, then quickly fixed the error. But Ebola programs are still in tatters, along with other livesaving efforts like AIDS treatments for children.
The Crackdown on Compounded GLP-1 Meds Has Begun
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” versions of its meds.
A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded versions of these GLP-1 medications, it’s a complicated situation.